Journal for Immunotherapy of Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 5, 2019 Category: Cancer & Oncology Source Type: research

Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes
ConclusionsOur observations indicate that sustained interactions between affinity-increased TCR and self-MHC can directly adjust the functional potential of T cells, even in the absence of antigen-specific stimulation. The observed tolerance-like state depends on TCR affinity and has therefore potential implications for the design of affinity-improved TCRs for adoptive T cell therapy, as several engineered TCRs currently used in clinical trials share similar affinity properties. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 4, 2019 Category: Cancer & Oncology Source Type: research

Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response
ConclusionsThe persistent complete response after third-line treatment for relapsed chemotherapy-resistant cervical cancer presented in this case highlights the potential of immunotherapy for patients with advanced cervical cancer impressively.To our knowledge, this is the first report of an isolated immune-related vulvitis under nivolumab. This adverse event might be underdiagnosed and mistreated, however, it is of importance due to its impact on quality of life, sexual wellbeing and compliance of patients. Successful IRAE management may enable prolonged immune checkpoint inhibitor therapy. In the future, routine molecula...
Source: Journal for Immunotherapy of Cancer - October 30, 2019 Category: Cancer & Oncology Source Type: research

Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer
ConclusionsThese data, together with important design considerations implied by the present study, suggest RAGE-ADCs could be translated to novel therapeutics for EC patients. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 28, 2019 Category: Cancer & Oncology Source Type: research

Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes
ConclusionsWe discover prominent and distinct associations between TIBs antibody isotypes and survival in lung adenocarcinoma carrying specific driver mutations. These findings indicate that particular types of tumor-immunity relations could be beneficial in particular driver mutation context, which should be taken into account in developing strategies of cancer immunotherapy and combination therapies. Specificity of protective B cell populations in specific cancer subgroups could become a clue to efficient targeted immunotherapies for appropriate cohorts of patients. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 28, 2019 Category: Cancer & Oncology Source Type: research

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
In conclusion, our findings indicate that PD-L1 expression as a predictive biomarker has limitations and that the decision to pursue testing mu st be carefully implemented for clinical decision-making. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 25, 2019 Category: Cancer & Oncology Source Type: research

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
ConclusionsBET Bromodomain inhibition can mediate changes in expression at a genome wide level in prostate cancer cells, resulting in an increased susceptibility to CD8 T cell targeting. These data suggest that combining BET bromodomain inhibition with immune checkpoint blockade may have clinical activity in prostate cancer patients. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 24, 2019 Category: Cancer & Oncology Source Type: research

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
ConclusionsOur studies elucidate some factors that underpin response and resistance to NY-ESO-1 SPEAR T-cell therapy. From these data, we conclude that a lymphodepletion regimen containing high doses of fludarabine and cyclophosphamide is necessary for SPEAR T-cell persistence and efficacy. Furthermore, these data demonstrate that non-T-cell inflamed tumors, which are resistant to PD-1/PD-L1 inhibitors, can be treated with adoptive T-cell based immunotherapy.Trial registrationClinicalTrials.gov,NCT01343043, Registered 27 April 2011. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 23, 2019 Category: Cancer & Oncology Source Type: research

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
ConclusionAvelumab showed clinical activity and a manageable safety profile in both the 1  L and 2 L treatment setting in patients with mRCC. These data support the use of avelumab in combination with other agents in mRCC.Trial registrationClinicalTrials.gov:NCT01772004; registered 21 January, 2013. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 23, 2019 Category: Cancer & Oncology Source Type: research

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
ConclusionsThis case report describes the evolution of TiME and TNBC molecular subtypes/genomics over time with sequential therapies in a TNBC patient with a CR to atezolizumab monotherapy. These data suggest the TiME is pliable and may be manipulated to maximize response to immunotherapy (NCT01375842,https://clinicaltrials.gov/ct2/show/NCT01375842?term=NCT01375842&rank=1). (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 22, 2019 Category: Cancer & Oncology Source Type: research

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
ConclusionsThis study demonstrated the feasibility of using phage display to discover small peptide-based checkpoint inhibitors. Our results also suggested that the anti-PD-L1 peptide represents a promising low-molecular-weight checkpoint inhibitor for cancer immunotherapy. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 21, 2019 Category: Cancer & Oncology Source Type: research

Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy
ConclusionsIn this study, we worked out two diagnostic methods for life-threatening infection during CAR T-cell therapy by analyzing inflammatory signatures, which contributed to reducing risks of infection-induced death. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 21, 2019 Category: Cancer & Oncology Source Type: research

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
ConclusionsThese results show for the first time that IGV SHMhigh and ongoing SHM have prognostic effects in DLBCL and potential implications for PD-1/PD-L1 blockade and neoantigen-based immunotherapies. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 21, 2019 Category: Cancer & Oncology Source Type: research

Correction to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma
Following publication of the original article [1], the author reported that the current funding section “Kidney Cancer Association Young Investigator Grant provided funding for this project” should be replaced with “Kidney Cancer Association Young Investigator Grant and Bucks County Board provided funding for this project.” (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 21, 2019 Category: Cancer & Oncology Source Type: research

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
ConclusionThese results demonstrate anti-tumor activity of PD-L1 inhibition in patients with relapsed thymoma accompanied by a high frequency of immune-related adverse events. Pre-treatment immune cell subset populations differ between responders and non-responders.Trial registrationClinicalTrials.gov -NCT01772004. Date of registration – January 21, 2013. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - October 20, 2019 Category: Cancer & Oncology Source Type: research